Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ENOV
ENOV logo

ENOV Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Enovis Corp (ENOV) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
26.270
1 Day change
-0.19%
52 Week Range
37.850
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Enovis Corp (ENOV) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are some positive indicators such as insider buying and a stable technical setup, the company's financial performance is weak, with significant declines in net income and EPS. The lack of recent news catalysts and no strong trading signals further suggest that this stock is better suited for monitoring rather than immediate investment.

Technical Analysis

The MACD is positive at 0.32, indicating a mild bullish momentum, but it is contracting. RSI at 74.032 is neutral, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting indecision in the market. Key support is at 22.61, and resistance is at 25.505, with the stock currently trading near resistance at 25.2.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
7

Positive Catalysts

  • Insiders are significantly buying, with a 372.22% increase in buying activity over the last month. Analysts maintain positive ratings, with price targets ranging from $35 to $42, suggesting potential upside.

Neutral/Negative Catalysts

  • There is no recent news or event-driven catalysts to support a strong bullish case. Additionally, the stock's next-week probability suggests a potential decline of -3.82%.

Financial Performance

In Q4 2025, revenue increased by 2.64% YoY to $575.76M, and gross margin improved by 6.33% to 53.93. However, net income dropped significantly by -25.98% to -$520.59M, and EPS fell by -27.66% to -9.1, indicating poor profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts maintain positive ratings with price targets ranging from $35 to $42. However, recent price target adjustments have been slightly lowered, reflecting cautious optimism.

Wall Street analysts forecast ENOV stock price to rise
9 Analyst Rating
Wall Street analysts forecast ENOV stock price to rise
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.320
sliders
Low
40
Averages
45.25
High
50
Current: 26.320
sliders
Low
40
Averages
45.25
High
50
William Blair
Outperform
initiated
$30s
AI Analysis
2026-04-17
New
Reason
William Blair
Price Target
$30s
AI Analysis
2026-04-17
New
initiated
Outperform
Reason
William Blair assumed coverage of Enovis with an Outperform rating. The firm believes the stock's valuation reflects investor skepticism. Enovis' execution on free cash flow improvement will be the most important driver of multiple expansion from current levels, the analyst tells investors in a research note. William Blair thins the company has set a more conservative bar with its 2026 underlying growth guidance at 4%-6%. It sees fair value for the shares in the low to mid-$30s 12 months out.
BTIG
Buy
downgrade
$43 -> $39
2026-04-13
Reason
BTIG
Price Target
$43 -> $39
2026-04-13
downgrade
Buy
Reason
BTIG lowered the firm's price target on Enovis to $39 from $43 and keeps a Buy rating on the shares as part of a broader research name on Medical Technology. The firm is updating its models to reflect the CMS having announced its proposed rule for the FY27 inpatient prospective payment system which includes, among other things, preliminary commentary and decisions regarding new technology add-on payments, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ENOV
Unlock Now

People Also Watch